{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:18:36Z","timestamp":1780323516945,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clineuro.2026.109389","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:18:58Z","timestamp":1773245938000},"page":"109389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin"],"prefix":"10.1016","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3989-0860","authenticated-orcid":false,"given":"Aki","family":"Yasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayane","family":"Tamagake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amane","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsukita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2026.109389_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health related quality of life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2026.109389_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013278","article-title":"Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross sectional study","volume":"7","author":"Nagane","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.clineuro.2026.109389_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2026.109389_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clineuro.2026.109389_bib5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2026.109389_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14712598.2023.2184257","article-title":"Biological therapies for myasthenia gravis","volume":"23","author":"Uzawa","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.clineuro.2026.109389_bib7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"ADAPT Investigator Study Group, Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2026.109389_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cccn.2004.05.008","article-title":"Muscle-specific receptor tyrosine kinase autoantibodies\u2013a new immunoprecipitation assay","volume":"348","author":"Matthews","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.clineuro.2026.109389_bib9","article-title":"ADAPT+ Study Group, Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2026.109389_bib10","article-title":"Achievement of minimal symptom expression and effect on disease-specific measures in acetylcholine receptor antibody-positive participants with generalized myasthenia gravis treated with efgartigimod in ADAPT\/ADAPT+","author":"Howard","year":"2024","journal-title":"Am. Acad. Neurol. Annu. Meet. USA"},{"key":"10.1016\/j.clineuro.2026.109389_bib11","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis","volume":"271","author":"Li","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2026.109389_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2025.110457","article-title":"The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients","volume":"274","author":"Zhang","year":"2025","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clineuro.2026.109389_bib13","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clineuro.2026.109389_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mus.28042","article-title":"Retrospective review of patients with myasthenia gravis switched from therapeutic plasma exchange to efgartigimod treatment","volume":"69","author":"Mehrabyan","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2026.109389_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2026.109389_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.28003","article-title":"Single institution experience with efgartigimod in patients with myasthenia gravis: patient selection, dosing schedules, treatment response, and adverse events","volume":"69","author":"Singer","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2026.109389_bib17","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real World experience with efgartigimod in patients with myasthenia gravis","volume":"271","author":"Fuchs","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2026.109389_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nmd.2024.04.005","article-title":"Retrospective analysis of efgartigimod use in patients with double seronegative generalized myasthenia gravis: a case series","volume":"39","author":"Horiuchi","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clineuro.2026.109389_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/mus.28184","article-title":"Efgartigimod in refractory autoimmune myasthenia gravis","volume":"70","author":"Remijn-Nelissen","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2026.109389_bib20","first-page":"e2062","article-title":"A randomized, double-blind, placebo-controlled trial of the corticosteroid-sparing effects of intravenous immunoglobulin in myasthenia gravis","volume":"98","author":"Bril","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2026.109389_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12883-024-03553-y","article-title":"Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa","volume":"24","author":"McCallion","year":"2024","journal-title":"BMC Neurol."},{"key":"10.1016\/j.clineuro.2026.109389_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/aian.aian_945_22","article-title":"Clinical profile and quality of life in myasthenia gravis using MGQOL15 R (Hindi)","volume":"26","author":"Majigoudra","year":"2023","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.clineuro.2026.109389_bib23","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/jpm13071130","article-title":"Evaluation of the quality of life of patients with myasthenia gravis in Greece","volume":"13","author":"Aggelina","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.clineuro.2026.109389_bib24","first-page":"240","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT","volume":"270","author":"Howard","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2026.109389_bib25","first-page":"3306","article-title":"Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan","volume":"30","author":"Mori","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clineuro.2026.109389_bib26","article-title":"Hospitalization and exacerbation estimates of efgartigimod vs. conventional therapy in generalized myasthenia gravis patients: a post-hoc analysis of the Phase 3 ADAPT study","volume":"25","author":"Qi","year":"2022","journal-title":"ISPOR Value Health"},{"key":"10.1016\/j.clineuro.2026.109389_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of refractory myasthenia gravis on health-related quality of life","volume":"20","author":"Boscoe","year":"2019","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.clineuro.2026.109389_bib28","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s12325-023-02604-z","article-title":"People diagnosed with Myasthenia Gravis have lower health-related quality of life and need more medical and caregiver help in comparison to the general population: analysis of two observational studies","volume":"40","author":"Dewilde","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.clineuro.2026.109389_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120268","article-title":"The humanistic burden of myasthenia gravis: a systematic literature review","volume":"437","author":"Gelinas","year":"2022","journal-title":"J. Neurol. Sci."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:49:28Z","timestamp":1775119768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846726000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"alternative-id":["S0303846726000818"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109389","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109389"}}